KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Moderna (MRNA) Payables: 2017-2024

Historic Payables for Moderna (MRNA) over the last 8 years, with Dec 2024 value amounting to $405.0 million.

  • Moderna's Payables fell 28.42% to $267.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.1 billion, marking a year-over-year decrease of 20.81%. This contributed to the annual value of $405.0 million for FY2024, which is 22.12% down from last year.
  • Per Moderna's latest filing, its Payables stood at $405.0 million for FY2024, which was down 22.12% from $520.0 million recorded in FY2023.
  • Moderna's 5-year Payables high stood at $520.0 million for FY2023, and its period low was $18.0 million during FY2020.
  • For the 3-year period, Moderna's Payables averaged around $470.7 million, with its median value being $487.0 million (2022).
  • Per our database at Business Quant, Moderna's Payables surged by 1,577.78% in 2021 and then fell by 22.12% in 2024.
  • Moderna's Payables (Yearly) stood at $18.0 million in 2020, then soared by 1,577.78% to $302.0 million in 2021, then soared by 61.26% to $487.0 million in 2022, then increased by 6.78% to $520.0 million in 2023, then dropped by 22.12% to $405.0 million in 2024.